Ellen Marin

Dec 19, 2023 | nature.com | Sara Scott |Ellen Marin |Kathryn T. Maples |Nisha Joseph |Craig C Hofmeister |Vikas Gupta | +3 more

Dear Editor,Teclistamab (Tecvayli®) is a first-in-class T-cell redirecting bispecific antibody that targets CD3 on the surface of T-cells and B-cell maturation antigen (BCMA) on plasma cells [1]. Teclistamab was approved by the FDA for patients with relapsed/refractory multiple myeloma (RRMM) after 4 lines of therapy including an immunomodulatory drug (IMID), proteasome inhibitor (PI), and anti-CD38 monoclonal antibody (mAb) based on the results of the phase 1/2 MajesTEC-1 study.

Dec 15, 2023 | cancernetwork.com | Sagar Lonial |Ellen Marin

2 Commerce Drive Cranbury, NJ 08512